Introduction {#sec1}
============

The increasing occurrence of resistance to carbapenems is a major issue for global public health. Resistance to carbapenems is often mediated by carbapenemases, with NDM-1 (New Delhi metallo-β-lactamase) being one of the most commonly identified carbapenemases worldwide, its main reservoir corresponding to the Indian subcontinent \[[@bib1]\]. Accordingly, several studies reported a high occurrence of NDM-1 producers in India and Pakistan \[[@bib2],[@bib3]\]. Most of the carbapenemase producers are co-resistant to other antibiotic families, so it is interesting to obtain further characterization about those co-resistance markers \[[@bib4]\]. Our aim was to characterize the carbapenemases, extended-spectrum β-lactamases (ESBLs), 16S rRNA methylases conferring pan-aminoglycoside resistance, and colistin resistance (plasmid-mediated *mcr* genes) from a series of clinical isolates obtained in acute-care facilities from Peshawar, Pakistan.

Materials and methods {#sec2}
=====================

Bacterial isolates {#sec2.1}
------------------

A total of 200 samples were collected from 200 individuals between December 2017 and March 2018 at the Khyber Teaching Hospital of Peshawar, north Pakistan. Those samples included urine, blood, pus and broncheal lavage specimens. Samples were plated on URIselect-4™ medium (Bio-Rad, Cressier, Switzerland) and identification was performed using the API-20E system (bioMérieux, La Balme-les-Grottes, France). Antimicrobial susceptibility testing was performed using the disc diffusion method and interpreted according to the CLSI recommendations \[[@bib5]\], except for colistin. Resistance to colistin was evaluated first by using the Rapid Polymyxin test \[[@bib6]\], and then by determination of MIC values of colistin by broth microdilution, as recommended by European Committee on Antimicrobial Susceptibility Testing (EUCAST) ([www.eucast.org](http://www.eucast.org){#intref0010}). Carbapenemase and ESBL activities were detected using the Carba NP test \[[@bib7]\] and the ESBL NP test \[[@bib8]\], respectively.

Molecular analysis {#sec2.2}
------------------

A series of acquired resistance genes were searched by PCR, including those encoding ESBLs (*bla*~TEM~-, *bla*~SHV~- and *bla*~CTX-M~-like genes), carbapenemases (*bla*~KPC~, *bla*~NDM~, *bla*~VIM~, *bla*~IMP~, *bla*~OXA-48~, *bla*~OXA-181~), 16S rRNA methylases genes (*armA*, *rmtA* to *rmtH* and *npmA*), and *mcr*-like genes (*mcr-1* to *mcr-8*) \[[@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]\]. The obtained amplicons were sent for sequencing (Microsynth®, Balgach, Switzerland).

Clonal diversity {#sec2.3}
----------------

Clonal relationship of the isolates was evaluated by pulsed-field gel electrophoresis (PFGE) \[[@bib15]\]. Total DNA from *Escherichia coli*, *Klebsiella pneumoniae* and *Enterobacter* spp. were digested using the *Xba*I enzyme (New England Biolabs, Ipswich, MA, USA). The generated fragments were separated by PFGE using a CHEF-DR III System (Bio-Rad) creating a unique PFGE profile for each clonal strain. Multilocus sequencing typing was performed for pan-drug aminoglycoside-resistant strains belonging to the species *E. coli* (strain no. 31) and *K. pneumoniae* (strain no. 62) \[[@bib16]\]. Sequence types (STs) were investigated using the online databases (<http://genomicepidemiology.org/>).

Results {#sec3}
=======

A total of 65 Gram-negative bacteria were recovered including 46 *E. coli*, 10 *Enterobacter* spp. (9 *Enterobacter cloacae*, 1 *Enterobacter sakazakii*), 6 *K. pneumoniae*, 2 *Alcaligenes faecalis* and 1 *Citrobacter freundii*.

Thirty-eight of the 65 Gram-negative bacteria produced a carbapenemase, as assessed by the results of the Rapid Carba NP test, whereas 32 of those 65 isolates produced an ESBL according to the results of the ESBL NP test. Among the 46 *E. coli* isolates, 12 produced NDM-1, 5 co-produced NDM-1 and CTX-M-15, 2 co-produced NDM-1 and OXA-181, 2 isolates co-producing OXA-181 and CTX-M-15, a single isolate producing OXA-48. Twelve *E. coli* isolates produced CTX-M-15 without any carbapenemase associated. A single *bla*~NDM-1~-positive *E. coli* isolate produced the 16S rRNA methylase RmtB.

Among the six *K. pneumoniae* isolates, one isolate co-produced NDM-1 and CTX-M-15, another co-produced NDM-1, OXA-181 and CTX-M-15, and a single isolate co-produced NDM-1, OXA-232 and CTX-M-15 together with the 16S rRNA methylase RmtB (see [Table 1](#tbl1){ref-type="table"}).Table 1Information and genetic features of samples isolated in Peshawar teaching hospital, PakistanTable 1Patient/strain no.Site of isolationResidenceTreatmentStrainsCarbapenemaseESBL16S RNA methyltransferaseClonality1PusPeshawarCiprofloxacin*Alcaligenes faecalis*VIM-4NoneNoneNone2UrineMardanOfloxine*Alcaligenes faecalis*VIM-4NoneNoneNone3UrineBatkhelaUnknown*Citrobacter freundii*NoneCTX-M-15NoneEsC-74PusPeshawarCiprofloxacin*Enterobacter cloacae*NDM-1NoneNoneEC-15UrinePeshawarUnknown*Enterobacter cloacae*NDM-1CTX-M-15NoneEC-16UrineKohatUnknown*Enterobacter cloacae*NDM-1CTX-M-15NoneEC-17BloodUnknownCefixime*Enterobacter cloacae*NDM-1CTX-M-15NoneEC-18UrineMardanOfloxine*Enterobacter cloacae*NDM-1CTX-M-15NoneEC-19UrineAfghanistanUnknown*Enterobacter cloacae*NDM-1CTX-M-15NoneEC-110UrineAfghanistanUnknown*Enterobacter cloacae*NDM-1CTX-M-15NoneEC-111UrinePeshawarLevofloxacin*Enterobacter cloacae*NDM-1CTX-M-15NoneNone12UrinePeshawarLevofloxacin*Enterobacter cloacae*NDM-1CTX-M-15NoneNone13UrinePeshawarUnknown*Enterobacter sakazakii*NDM-1CTX-M-15NoneNone14FluidPeshawarCiprofloxacin*Escherichia coli*NDM-1NoneNoneNone15PusCharsadaCiprofloxacin*Escherichia coli*NDM-1NoneNoneNone16PusDirAmoxicillin*Escherichia coli*NDM-1NoneNoneNone17PusPeshawarLevofloxacin*Escherichia coli*NDM-1NoneNoneNone18PusPeshawarLevofloxacin*Escherichia coli*NDM-1NoneNoneNone19PusPeshawarUnknown*Escherichia coli*NDM-1NoneNoneNone20PusPeshawarUnknown*Escherichia coli*NDM-1NoneNoneNone21UrinePeshawarCeftriaxone*Escherichia coli*NDM-1NoneNoneNone22UrinePeshawarCiprofloxacin*Escherichia coli*NDM-1NoneNoneNone23UrinePeshawarUnknown*Escherichia coli*NDM-1NoneNoneNone24UrinePeshawarUnknown*Escherichia coli*NDM-1NoneNoneNone25UnknownPeshawarCefixime*Escherichia coli*NDM-1NoneNoneNone26BloodMardanUnknown*Escherichia coli*NDM-1CTX-M-15NoneNone27BloodPeshawarUnknown*Escherichia coli*NDM-1CTX-M-15NoneEsC-1528UrinePeshawarUnknown*Escherichia coli*NDM-1CTX-M-15NoneNone29UrinePeshawarUnknown*Escherichia coli*NDM-1CTX-M-15NoneNone30UrinePeshawarUnknown*Escherichia coli*NDM-1CTX-M-15NoneNone31UnknownUnknownUnknown*Escherichia coli*NDM-1NonermtBST 21532UrinePeshawarCiprofloxacin*Escherichia coli*NDM-1; OXA-181NoneNoneEsC-1033UrinePeshawarUnknown*Escherichia coli*NDM-1; OXA-181NoneNoneNone34UrinePeshawarCiprofloxacin*Escherichia coli*OXA-48NoneNoneEsC-135BloodPeshawarCiprofloxacin*Escherichia coli*OXA-181CTX-M-15NoneEsC-536BloodPeshawarUnknown*Escherichia coli*OXA-181CTX-M-15NoneEsC-137BloodKohatUnknown*Escherichia coli*NoneCTX-M-15NoneEsC-1438PusDirUnknown*Escherichia coli*NoneCTX-M-15NoneEsC-239PusPeshawarOfloxine*Escherichia coli*NoneCTX-M-15NoneEsC-240UrinePeshawarAmoxicillin-Clavulanate*Escherichia coli*NoneCTX-M-15NoneEsC-241UrinePeshawarLevofloxacin*Escherichia coli*NoneCTX-M-15NoneEsC-242Bronchial lavagePeshawarLevofloxacin*Escherichia coli*NoneCTX-M-15NoneEsC-343PusPeshawarCefixime*Escherichia coli*NoneCTX-M-15NoneEsC-344UrinePeshawarUnknown*Escherichia coli*NoneCTX-M-15NoneEsC-345UrineKohatUnknown*Escherichia coli*NoneCTX-M-15NoneEsC-346UrinePeshawarCiprofloxacin*Escherichia coli*NoneCTX-M-15NoneEsC-947UrinePeshawarLevofloxacin*Escherichia coli*NoneCTX-M-15NoneEsC-1248UrineAfghanistanLevofloxacin*Escherichia coli*NoneCTX-M-15NoneNone49BloodPeshawarCefixime*Escherichia coli*NoneNoneNoneEsC-1650BloodUnknownCefixime*Escherichia coli*NoneNoneNoneEsC-1351PusAfghanistanUnknown*Escherichia coli*NoneNoneNoneEsC-1152PusCharsadaCiprofloxacin*Escherichia coli*NoneNoneNoneNone53PusPeshawarCiprofloxacin*Escherichia coli*NoneNoneNoneNone54PusPeshawarLinezolid*Escherichia coli*NoneNoneNoneEsC-1855UrineAfghanistanUnknown*Escherichia coli*NoneNoneNoneEsC-1756UrinePeshawarCefixime*Escherichia coli*NoneNoneNoneEsC-457UrinePeshawarUnknown*Escherichia coli*NoneNoneNoneEsC-458UrinePeshawarUnknown*Escherichia coli*NoneNoneNoneEsC-659UrinePeshawarUnknown*Escherichia coli*NoneNoneNoneEsC-860BloodPeshawarCefixime*Klebsiella pneumoniae*NDM-1CTX-M-15NoneKP-161PusDirAmoxicillin*Klebsiella pneumoniae*NDM-1; OXA-181NoneNoneKP-162BloodMardanUnknown*Klebsiella pneumoniae*NDM-1; OXA-232CTX-M-15rmtBST 23163PusPeshawarCiprofloxacin*Klebsiella pneumoniae*NoneNoneNoneKP-264UrineNoweshehraCiprofloxacin*Klebsiella pneumoniae*NoneNoneNoneKP-265UnknownAfghanistanLevofloxacin*Klebsiella pneumoniae*NoneNoneNoneNone[^1]

The ten *Enterobacter* spp. isolates (nine *Enterobacter cloacae*, one *Enterobacter sakazakii*) co-produced NDM-1 and CTX-M-15.

Two *Alcaligenes faecalis* isolates were identified, both producing a carbapenemase VIM-4.

The single *C. freundii* isolate did not produce any carbapenemase but was positive for CTX-M-15. None of the isolates was resistant to colistin. PFGE analysis showed a very high clonal diversity for all those isolates producing a carbapenemase, except among *Enterobacter* spp. with a single clone being identified among six patients (EC-1) that may have resulted from an outbreak.

By using MLST, we showed that the *bla*~NDM-1~ and *rmtB*-positive *E. coli* clone belonged to ST215 (strain no. 31) and that the multidrug-resistant *K. pneumoniae* isolate belonged to ST231 (strain no. 62).

Discussion {#sec4}
==========

Here we evaluated the occurrence of multidrug resistance from infecting strains (not colonizers) from individuals hospitalized at the Khyber Teaching Hospital, Peshawar, north Pakistan from November 2017 to March 2018. A rate of 19% of carbapenem-resistant *Enterobacteriaceae* (38/200) was identified, among which 16% harboured the *bla*~NDM-1~ gene. This overall rate of 16% of NDM producers is in accordance with the estimated rate of NDM producers in *Enterobacteriaceae* in Pakistan (8.7%--18.5%). Actually, 18.5% stool samples were found to contain *bla*~NDM-1~-positive strains (mostly *E. coli* and *Enterobacter cloacae*) in military hospitals of Rawalpindi (Combined Military Hospitals and Military Hospital at Rawalpindi) \[[@bib17]\], 8.7% of the isolates were NDM-1 positive (*K. pneumoniae*, *E. coli*, *Pseudomonas aeruginosa*) from two tertiary-care hospitals (Pakistan Institute of Medical Science, Islamabad and Mayo Hospital, Lahore) \[[@bib18]\] and 14.6% of the strains carried *bla*~NDM-1~ (*E. coli*, *Enterobacter cloacae*, *Pseudomonas putida* and *K. pneumoniae* from three children\'s hospitals (The Children\'s Hospital, Islamabad, The Children\'s Hospital Multan and Nishtar Hospital, Multan) \[[@bib19]\].

Interestingly, some strains were found to harbour two unrelated carbapenemase genes (*bla*~NDM-1~ and *bla*~OXA-181~), as observed previously in Singapore \[[@bib20]\], Nigeria \[[@bib21]\] and Romania \[[@bib22]\].

In our study, co-resistance to multiple antibiotics was commonly observed among those carbapenem-resistant isolates, with 60% of them harbouring at least two other resistance genes (ESBL, or 16S rRNA methylase gene). A single *K. pneumoniae* isolate carried two carbapenemase genes, namely *bla*~NDM-1~ and *bla*~OXA-232~, along with the ESBL-encoding gene *bla*~CTX-M-15~ and the 16S rRNA methylase gene *rmtB*. That isolate was an ST231 clone, already described in South-East Asia \[[@bib23],[@bib24]\] and Switzerland \[[@bib25]\], and associated with OXA-232.

Among the 16S rRNA methylase genes, the methylase gene *rmtB*, rather than *rmtF*, was mostly identified here, which is not surprising owing to the spread of *rmtB*-positive strains in Pakistan \[[@bib26]\]. Our study showed the frequent identification of the ESBL CTX-M-15 among those multidrug-resistant bacteria. It is possible that the spread of CTX-M-15 that is observed worldwide originated from the Indian subcontinent because we identified the first CTX-15 producers from India in 2001 \[[@bib27]\]. Our study confirms the frequent association of those three important resistance markers that are NDM, ESBL of the CTX-M-15 type and 16S rRNA methylases as a source of multidrug resistance. This combination complicates the treatment of infected patients.

We also identified two *A. faecalis* isolates producing a same VIM-4 metallo-β-lactamase. Occurrence of carbapenemase production in that bacterial species is rare. Only a single case of *A. faecalis* carrying *bla*~VIM-4~ has been described in Gaza, Palestine \[[@bib28]\]. Further work may identify the genetic basis of such acquisition of carbapenemase. Other reports about ESBL in clinical isolates of *Alcaligenes* species have been described in Malaysia \[[@bib29]\], France \[[@bib30]\] and Italy \[[@bib31]\].

Finally, no resistance to colistin was observed whereas MCR-1-mediated colistin resistance isolates was observed recovered from *E. coli* in animals \[[@bib32],[@bib33]\] and from a single patient \[[@bib34]\] in Pakistan. Lack of colistin resistance among those multidrug-resistant isolates is good news as it would indicate the availability to use that drug for treating infected patients in this country.
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[^1]: Abbreviations: EC, *Enterobacter cloacae* clone X; ESBL, extended spectrum β-lactamase; EsC, *Escherichia coli* clone X; KP, *Klebsiella pneumoniae* clone X; ST, sequence type.
